Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-26
2005-07-26
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reexamination Certificate
active
06921764
ABSTRACT:
The present invention relates to novel quinazolin-4-one derivatives of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
REFERENCES:
patent: 5284957 (1994-02-01), Huff
patent: 5426106 (1995-06-01), Kulagowski et al.
patent: 6136812 (2000-10-01), Chenard et al.
patent: 0459561 (1991-12-01), None
patent: 0481676 (1992-04-01), None
patent: WO 9311115 (1993-06-01), None
patent: WO 9519346 (1995-07-01), None
Rogawski et al., PubMed Abstract (Adv Neurol 79:947-63), 1999.
Liu et al., PubMed Abstract (Proc Natl Sci USA, 101(9):3172-7), Mar. 2004.
Broadbent et al., PubMed Abstract (Psychopharmacology (Berl). 167(3):225-34), Apr. 2003.
Sang et al., Abstract #S27.002, May 2001.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Watkins, J.C, and Evans, R.H., Excitatory Amino Acid Transmitters, Annu. Rev. Pharmacol. Toxicol. 21, pp. 165-204 (1981).
Monaghan, Daniel T., et al., The Excitatory Amimo Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System, Annu. Rev. Parmacol. Toxicol. 29 pp. 365-402 (1989).
Watkins, Jeff C., et al., Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists, TIPS- (vol. 11) pp. 25-33 Jan. 1990.
Schoepp, Darryle, et al., Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors, TIPS- (vol. 11) pp. 508-515 Dec. 1990.
McDonald, John W. and Johnston, Michael V., Physiological and pathophysiological roles of excitatory amino acids during central nervous system development, Brain Res. Reviews 15, pp. 41-70 (1990).
Sheardown, Malcom J., et al., 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline: A Neuroprotectant for Cerebral Ischemia, Science Reports, vol. 247, pp. 571-574 Feb. 2, 1990.
Buchan, Alastair M., et al., Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia, NeuroReport 2, No. 8, pp. 473-476 (1991).
Le Peillet, Elaine, et al., The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat, Brain Res. 571, pp. 115-120 (1992).
Parks T.N., et al., Modulation of N-methyl-D-aspartate receptor-mediated increases in cytosolic calcium in cultured rat cerebellar granule cells, Brain Res. 552, pp. 13-22 (1991).
Physicians' Desk Reference, 53 Ed., 1999, pp. 2604-2607.
Meldrum, B.S. Current Opinion in Neurology and Neurosurgery, vol. 5, 1992, pp. 508-513.
Keppelle, L.J. et al. Pharmaceutisch Weekblad, vol. 132 No. 31, 1997, pp. 1117-1123.
Jackson, C.E. et al. Seminars in Neurology, vol. 18, No. 1, 1998, pp. 27-39.
Hughes, A.J. Drugs, vol. 53, No. 2, 1997, pp. 195-205.
Greenamyre, J.T. Neurobiology of Aging, 1989, vol. 10, pp. 593-602.
Medline abstract no. 92274400: Giuffra, M.E. et al. Clinical Neuropharmacology, 1992, vol. 15, No. 2, pp. 148-151.
Medline abstract no. 97339045: Montastruc, J.L. et al. Neuroscience and Biobehavioural Reviews, 1997, vol. 21, No. 4, pp. 477-480.
Chalmers et al. TIPS, 1996, vol. 17, pp. 166-172.
Frampton et al. Drugs and Aging, 1995, vol. 7, No. 6, pp. 480-503.
Lyrer Schweiz. Med. Wochenschr. 1994, vol. 124, No. 45, pp. 2005-2012.
Chenard Bertrand L
Reinhold Anthony R.
Welch Willard M
Jubinsky James A.
Ling Lorraine B.
Pfizer Inc.
Rao Deepak
Richardson Peter C.
LandOfFree
Thieno-pyrimidin-4-one AMPA antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno-pyrimidin-4-one AMPA antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno-pyrimidin-4-one AMPA antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370463